FOXO3 Upregulation Therapy — Gene Therapy & Genetic Interventions
Genetic or pharmacological upregulation of the FOXO3 longevity gene to enhance stress resistance and autophagy.
Overview
FOXO3 (Forkhead box O3) is one of the most replicated longevity-associated genes in human GWAS studies. The FOXO3 rs2802292 G-allele is associated with a 2.7-fold increased odds of reaching 100 years. FOXO3 activates autophagy, antioxidant defense, DNA repair, and apoptosis of damaged cells. Gene therapy approaches aim to deliver constitutively active FOXO3 or use CRISPR activation (CRISPRa) to upregulate endogenous FOXO3 expression. Pharmacological activators of FOXO3 are also under investigation.
Indications
- Longevity and healthspan extension
- Enhanced cellular stress resistance
- Autophagy induction
- Cancer chemoprevention (preclinical)
- Cardiovascular protection
Mechanism of Action
FOXO3 translocates to the nucleus upon dephosphorylation (via AMPK activation or AKT inhibition)
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| AAV-FOXO3a (constitutively active) | Study-specific | Single infusion | Preclinical concept; no standardized dosing |
| CRISPRa-FOXO3 (dCas9-VPR) | Study-specific | Single treatment | Epigenetic activation of endogenous FOXO3 locus |
Evidence Grade
GRADE D
Safety & Contraindications
- Excessive FOXO3 activation may impair stem cell function and tissue regeneration
- FOXO3 can promote muscle atrophy via atrogin-1 and MuRF1 induction
- Balance between tumor suppression and stem cell maintenance is critical
- No human gene therapy trials for FOXO3 upregulation
- Pharmacological approaches (e.g., via AMPK/SIRT1 activation) are indirect